:--------------------------:
: OMB APPROVAL :
:--------------------------:
:OMB Number: 3235-0145:
UNITED STATES :Expires: November 30, 1999:
SECURITIES AND EXCHANGE COMMISSION :Estimated average burden :
WASHINGTON, D.C. 20549 :hours per response . 14.90:
:--------------------------:
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 3 )*
Duramed Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, Par Value $0.01 Per Share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
266354 10 9
---------------------------------------------------------------------------
(CUSIP Number)
Jeffrey D. Linton
Vice President, Law, Government and
Public Affairs
Solvay Pharmaceuticals, Inc.
901 Sawyer Road
Marietta, Georgia 30062
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
December 3, 1999
---------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box [_].
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See ss. 240.13d-7 for other
parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SEC 1746(12-91)
<PAGE>
SCHEDULE 13D
- --------------------- ------------------
CUSIP NO. 266354 10 9 Page 2 of 7 Pages
- --------------------- ------------------
- -------------------------------------------------------------------------------
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Solvay Pharmaceuticals, Inc.
- -------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A) [_]
(SEE INSTRUCTIONS) (B) [_]
- -------------------------------------------------------------------------------
3. SEC USE ONLY
- -------------------------------------------------------------------------------
4. SOURCE OF FUNDS (SEE INSTRUCTIONS)
WC
- -------------------------------------------------------------------------------
5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
[_]
- -------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Georgia
- -------------------------------------------------------------------------------
NUMBER OF 7. SOLE VOTING POWER
SHARES 3,000,000
BENEFICIALLY --------------------------------------------------------------
OWNED BY 8. SHARED VOTING POWER
EACH -0-
REPORTING --------------------------------------------------------------
PERSON 9. SOLE DISPOSITIVE POWER
WITH 3,000,000
--------------------------------------------------------------
10. SHARED DISPOSITIVE POWER
-0-
- -------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,000,000
- -------------------------------------------------------------------------------
12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) [_]
- -------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
12.1%
- -------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- -------------------------------------------------------------------------------
<PAGE>
SCHEDULE 13D
- --------------------- ------------------
CUSIP NO. 266354 10 9 Page 3 of 7 Pages
- --------------------- ------------------
- -------------------------------------------------------------------------------
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Solvay America, Inc.
- -------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A) [_]
(SEE INSTRUCTIONS) (B) [_]
- -------------------------------------------------------------------------------
3. SEC USE ONLY
- -------------------------------------------------------------------------------
4. SOURCE OF FUNDS (SEE INSTRUCTIONS)
AF
- -------------------------------------------------------------------------------
5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
[_]
- -------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- -------------------------------------------------------------------------------
NUMBER OF 7. SOLE VOTING POWER
SHARES 3,000,000
BENEFICIALLY --------------------------------------------------------------
OWNED BY 8. SHARED VOTING POWER
EACH -0-
REPORTING --------------------------------------------------------------
PERSON 9. SOLE DISPOSITIVE POWER
WITH 3,000,000
--------------------------------------------------------------
10. SHARED DISPOSITIVE POWER
-0-
- -------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,000,000
- -------------------------------------------------------------------------------
12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) [_]
- -------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
12.1%
- -------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- -------------------------------------------------------------------------------
<PAGE>
SCHEDULE 13D
- --------------------- ------------------
CUSIP NO. 266354 10 9 Page 4 of 7 Pages
- --------------------- ------------------
- -------------------------------------------------------------------------------
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Solvay S.A.
- -------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A) [_]
(SEE INSTRUCTIONS) (B) [_]
- -------------------------------------------------------------------------------
3. SEC USE ONLY
- -------------------------------------------------------------------------------
4. SOURCE OF FUNDS (SEE INSTRUCTIONS)
AF
- -------------------------------------------------------------------------------
5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
[_]
- -------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Belgium
- -------------------------------------------------------------------------------
NUMBER OF 7. SOLE VOTING POWER
SHARES 3,000,000
BENEFICIALLY --------------------------------------------------------------
OWNED BY 8. SHARED VOTING POWER
EACH -0-
REPORTING --------------------------------------------------------------
PERSON 9. SOLE DISPOSITIVE POWER
WITH 3,000,000
--------------------------------------------------------------
10. SHARED DISPOSITIVE POWER
-0-
- -------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,000,000
- -------------------------------------------------------------------------------
12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) [_]
- -------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
12.1%
- -------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
HC, OO
- -------------------------------------------------------------------------------
<PAGE>
CUSIP Number: 266354 10 9 Page 5 of 7
Solvay Pharmaceuticals, Inc., a Georgia corporation ("Solvay
Pharmaceuticals"), Solvay America, Inc., a Delaware corporation ("Solvay
America") and Solvay S.A., a Belgian societe anonyme ("Solvay S.A." and together
with Solvay Pharmaceuticals and Solvay America, the "Reporting Persons") hereby
amend the Report of Beneficial Ownership on Schedule 13D (the "Original Schedule
13D") filed by the Reporting Persons on October 18, 1999, as amended on October
21, 1999 and October 26, 1999, with respect to shares of Common Stock, par value
$.01 per share (the "Shares"), of Duramed Pharmaceuticals, Inc., a Delaware
corporation ("Duramed") beneficially owned by them. Capitalized terms used but
not defined herein shall have the meaning attributed to such terms in the
Original Schedule 13D.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
Item 3 is further amended as follows:
On December 3, 1999, the Federal Trade Commission granted early
termination of the waiting period pursuant to the HSR Act, at which time Solvay
Pharmaceuticals could exercise the remainder of its option to acquire 1,333,334
additional Shares of Duramed pursuant to the Option Agreement and the Subsequent
Subscription Agreement. Solvay Pharmaceuticals intends to purchase these Shares
on December 13, 1999.
ITEM 4. PURPOSE OF TRANSACTION
Item 4 is further amended as follows:
On December 3, 1999, the Federal Trade Commission granted early
termination of the waiting period pursuant to the HSR Act, at which time Solvay
Pharmaceuticals could exercise the remainder of its option to acquire 1,333,334
additional Shares of Duramed pursuant to the Option Agreement and the Subsequent
Subscription Agreement. Solvay Pharmaceuticals intends to purchase these Shares
on December 13, 1999.
<PAGE>
CUSIP Number: 266354 10 9 Page 6 of 7
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
Paragraph (a) of Item 5 of the Original Schedule 13D is amended in its
entirety as follows:
(a) The percentage interest held by each Reporting Person presented
below is based on the number of Shares that Duramed reported to be issued and
outstanding on November 9, 1999 in its Quarterly Report on Form 10-Q for the
fiscal year ended June 30, filed with the SEC on November 15, 1999, as adjusted
to give effect to the issuance of the remaining 1,333,334 Shares to the
Reporting Persons by Duramed (the "Outstanding Shares").
Solvay Pharmaceuticals beneficially owns 3,000,000 Shares of Duramed,
representing approximately 12.1% of the Outstanding Shares.
Solvay America and Solvay S.A. may be each deemed to beneficially own
3,000,000 Shares of Duramed, representing approximately 12.1% of the Outstanding
Shares.
None of the Reporting Persons, and to the knowledge of the Reporting
Persons, none of the persons listed in Schedules I and II hereto beneficially
owns any Shares of Duramed other than as set forth herein.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS
WITH RESPECT TO SECURITIES OF THE ISSUER
Item 6 is amended as follows:
On December 3, 1999, the Federal Trade Commission granted early
termination of the waiting period pursuant to the HSR Act, at which time Solvay
Pharmaceuticals could exercise the remainder of its option to acquire 1,333,334
additional Shares of Duramed pursuant to the Option Agreement and the Subsequent
Subscription Agreement. Solvay Pharmaceuticals intends to purchase these Shares
on December 13, 1999.
<PAGE>
CUSIP Number: 266354 10 9 Page 7 of 7
SIGNATURE
After reasonable inquiry and to the best of our knowledge and belief,
we certify that the information set forth in this statement is true, complete
and correct.
Dated: December 7, 1999
SOLVAY PHARMACEUTICALS, INC.
By: /s/ Jeffrey D. Linton
------------------------------
Name: Jeffrey D. Linton
Title: Vice President, Law,
Government and Public
Affairs
SOLVAY AMERICA, INC.
By: /s/ E.J. Buckingham, III
------------------------------
Name: E.J. Buckingham, III
Title: Vice President, General
Counsel and Secretary
SOLVAY S.A.
By: /s/ Rene H. Degreve
------------------------------
Name: Rene H. Degreve
Title: General Manager, Finance
and Corporate Planning
<PAGE>
INDEX TO EXHIBITS
Exhibit No. Exhibit
99.2 Joint Filing Statement, dated as of October 15,
1999, between Solvay Pharmaceuticals, Inc., Solvay
America, Inc. and Solvay S.A. (incorporated by
reference to Exhibit 99.2 of the Report of
Beneficial Ownership on Schedule 13D, filed with
the Securities and Exchange Commission on October
18, 1999).
